Peg-IFNα-2b联合利巴韦林治疗基因1/6型慢性丙型肝炎患者临床研究*

doi:10.3969/j.issn.1672-5069.2019.01.015

摘要/Abstract

摘要： 目的探讨应用聚乙二醇化干扰素α（Peg-IFNα）联合利巴韦林（RBV）治疗基因1/6型慢性丙型肝炎（CHC）患者的临床疗效。方法随机将246例慢性丙型肝炎（CHC）患者分为观察组123例和对照组123例,分别接受Peg-IFNα-2b 80 μg或Peg-IFNα-2a 180 μg皮下注射,1次/w,两组均同时口服利巴韦林,治疗48 w,随访24 w。采用罗氏公司COBAS Taqman HCV实时定量PCR试剂检测血清HCV RNA,采用Abbott RealTime HCV Genotype II试剂检测HCV基因型。结果观察组和对照组基线基因1型感染者分别为104例（84.6%）和108例（87.8%）,基因6型感染者分别为19例（15.4%）和15例（12.2%,P>0.05）,血清HCV RNA水平分别为（7.17±0.89） lg copies/ml和（7.19±0.88） lg copies/ml,白细胞计数分别为（6.6±1.3）×10⁹/L和（6.6±1.5）×10⁹/L,血小板计数分别为（154.1±21.1）×10⁹/L和（157.2±19.2）×10⁹/L,血清ALT水平分别为（83.4±26.3） U/L和（80.3±29.4）U/L,均无显著性相差（P>0.05）;观察组快速病毒学应答率（RVR）、早期病毒学应答率（EVR）、治疗结束时病毒学应答率（ETVR）和持续病毒学应答率（SVR）分别为45.5%、82.1%、83.7%和85.4%,与对照组的43.1%、78.9%、79.7%和78.0%比,无显著性差异（P>0.05）,两组停药后复发率分别为14.6%和22.0%,也无显著性相差（P>0.05）;在治疗过程中,观察组与对照组发热（58.5%对61.0%）、肌肉酸痛（48.8%对51.2%）、乏力（41.5%对44.7%）、头痛（30.9%对34.1%）、厌食（25.2%对30.1%）、脱发（26.8%对30.9%）、失眠（20.3%对25.2%）、白细胞下降（27.6%对31.7%）、红细胞下降（23.6%对28.5%）、血小板下降（13.8%对17.9%）和血清T3/T4/TSH异常（8.9%对10.6%）等不良反应发生率比较,均无显著性差异（P>0.05）。结论应用Peg-IFNα-2b或Peg-IFNα-2a治疗基因1/6型CHC患者,疗效较好,且两种干扰素治疗效果相当,安全性较好,值得临床应用。

关键词: 慢性丙型肝炎, 聚乙二醇化干扰素α, 基因1/6型, 治疗

Abstract: Objective To investigate the clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C（CHC） and genotype one and six infection. Methods A total of 246 patients with CHC were enrolled in this study,and the patients were randomly divided into observation group （n=123） and control group （n=123）,receiving peg-IFNα-2b 80 μg,or peg-IFNα-2a 180 μg subcutaneously once a week,respectively,and the patients with CHC in both groups received ribavirin orally for 48 weeks. All patients were followed-up for 24 weeks after discontinuation of the regimen. Serum HCV RNA and HCV genotypes were detected routinely by Abbott RealTime HCV Genotype II kits. Results At baseline, the genotype one of HCV infection in the observation and control groups were 84.6% and 87.8%,and genotype six infection were 15.4% and 12.2% （P>0.05）,serum HCV RNA levels were（7.17±0.89） lg copies/ml and （7.19±0.88） lg copies/ml,white blood cell counts were （6.6±1.3）×10⁹/L and （6.6±1.5）×10⁹/L,platelet counts were （154.1±21.1）×10⁹/L and （157.2±19.2）×10⁹/L,serum ALT levels were（83.4±26.3） U/L and （80.3±29.4） U/L,all without significant differences （P>0.05）;the rapid virologic response（RVR）,early virologic response（EVR）,end-treatment virologic response（ETVR） and sustained virologic response rates（SVR） in the observation group were 45.5%, 82.1%,83.7% and 85.4%,no significant differences as compared to 43.1%,78.9%,79.7% and 78.0%,respectively in the control （P>0.05）,and the relapse rates in the two groups were 14.6% and 22.0%（P>0.05）;during the injection of interferon-α,there were no significant differences as compared to the side effects such as the fever （58.5% vs. 61.0%）,muscle aches（48.8% vs. 51.2%）,fatigue （41.5% vs. 44.7%）,headaches （30.9% vs. 34.1%）,anorexia（25.2% vs. 30.1%）,hair loss （26.8% vs. 30.9%）,insomnia（20.3% vs. 25.2%）,leukopenia（27.6% vs. 31.7%）,declined erythrocyte counts（23.6% vs. 28.5%）,thrombocytopenia （13.8% vs. 17.9%） and serum T3/T4/TSH level abnormal （8.9% vs. 10.6%,all P>0.05）. Conclusions Application of peg-IFNα-2b and peg-IFNα-2a show similar efficacy and safety in the treatment of patients with CHC with genotype 1/6 infection,which is worthy of further clinical observation.

Key words: Chronic hepatitis C, Peg-IFNα-2b, Peg-IFNα-2a, Genotype 1/6, Therapy

侯春阳, 马玉梅, 李方治. Peg-IFNα-2b联合利巴韦林治疗基因1/6型慢性丙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 53-56.

Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.

参考文献

[1] Tagadeen M,Sabra A M,Akazawa Y,et al.Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement. Hepatic Med Evid Res,2017,9(4):45-53.
[2] 段军民,李素森,刘丽珍,等. 聚乙二醇干扰素α-2a与普通干扰素α-2b联合利巴韦林治疗慢性丙型肝炎患者疗效比较和影响疗效的预测因素分析.实用肝脏病杂志,2018,1(1):64-67.
[3] 娜丽. 慢性丙型肝炎患者外周血IL-28B基因型多态性及其对持续病毒学应答的影响. 实用肝脏病杂志,2017,20(5):600-601.
[4] 张馨,汪茂荣,杨志国,等. 聚乙二醇化干扰素α-2a、聚乙二醇化干扰素α-2b和干扰素α-2b联合利巴韦林治疗慢性丙型肝炎的疗效.中华实验和临床感染病杂志(电子版),2017,11(2):134-140.
[5] Péres D P,Cheinquer H,Wolf F H,et al.Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients. Ann Hepatol,2013,12(6):871-877.
[6] Cox-North P,Hawkins KL,Rossiter ST,et al.Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Ann Hepatol,2017,1(3):248-255.
[7] Takeshita Y,Takamura T,Kita Y,et al.Beneficial effect of branched-chain amino acid supplementation on glycemic control in chronic hepatitis C patients with insulin resistance:implications for type 2 diabetes. Metabolism,2012,61(10):1388-1394.
[8] Conti F,Brillanti S,Buonfiglioli F,et al.Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat,2017,24(6):454-463.
[9] Mohamed SY,Mostafa EF,Hanafy AS,et al.The relationship between expression of Toll-like receptor 4 in chronic hepatitis C patients and different stages of liver fibrosis. Gastroenterol Hepatol Bed Bench,2017,10(4):278-283.
[10] Dowran R,Sarvari J,Moattari A,et al.Analysis of TLR7,SOCS1 and ISG15 immune genes expression in the peripheral blood of responder and non-responder patients with chronic Hepatitis C. Gastroenterol Hepatol Bed Bench,2017,10(4):272-277.
[11] Valadez JA,Juárez IG,Pedrero RR,et al.Management of chronic hepatitis C virus infection in patients with end-stage renal disease:a review. Ther Clin Risk Manag,2015,2015(default):329-338.
[12] Gregory A,Penrose K,Morrison C,et al.Psychometric properties of the breastfeeding self-efficacy scale-short form in an ethnically diverse U.K. sample. Public Health Nurs,2008,25(3):278-284.
[13] Al-Busafi SA,Al-Shuaili H,Omar H,et al.Epidemiology of chronic hepatitis C infections at a tertiary care centre in oman. Sultan Qaboos Univ Med J,2018,17(4):404-410.
[14] Hansen JF,Hallager S,vrehus A,et al. Late presentation for care among patients with chronic hepatitis C:prevalence and risk factors. Open Forum Infect Dis,2018,5(1):1634-1637.
[15] Chung E,Park K,Kim JH,et al.Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFNα-2b. Korean J Intern Med,2017,92(2):156-166.
[16] Mangia A,Foster GR,Berg CP,et al.Efficacy and safety profile of boceprevir-or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C:the real-world PegBase observational study. Ann Gastroenterol,2017,30(3):327-331.
[17] Lawson BO,Khong HT.Narcoleptic-like episodes in a patient receiving pegylated interferon-alpha 2b:a case report and review of literature. Anticancer Res,2017,37(3):1365-1369.
[18] Brohl AS,Khushalani NI,Eroglu Z,et al.A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer,2016,4(1):85-89.
[19] Kumada H,Mochida S,Suzuki F,et al.Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1(GT1b) infection:phase 3 studies. J Gastroen Hepatol,2016,31(10):1674-1683.
[20] Mogahed EA,Abdelaziz H,Helmy H,et al.Safety and efficacy of pegylated interferon alpha-2b monotherapy in hepatitis C virus-infected children with end-stage renal disease on hemodialysis. J Interferon Cytokine Res,2016,36(12):1378-1382.
[21] Jin CN,Chen JD,Sheng JF. Vitamin D deficiency in hepatitis C virus infection:what is old what is new Eur J Gastroenterol Hepatol,2018,47(6):1378-1382.
[22] Colucci G,D'Ambrosio R,Galmozzi E,et al. Chemokine receptor 5 has no major role in the severity of hepatitis C virus-related liver damage. Viral Immunol,2018,12(9):384-395.
[23] Shiha G,Soliman R,ElBasiony M,et al. Sofosbuvir plus daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients:real-life experience. Hepatol Int,2018,25(12):619-624.

Peg-IFNα-2b联合利巴韦林治疗基因1/6型慢性丙型肝炎患者临床研究^*

Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[6]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[7]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[8]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[9]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[10]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[11]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[12]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[13]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[14]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[15]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.